Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
Eli Lilly shares surge following a CHMP recommendation for the EU approval of Jaypirca to treat chronic lymphocytic leukemia.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of pirtobrutinib (Jaypirca) in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. This follows a meeting held from June 22-25, 2026.
Coverage from Yahoo Finance, TradingKey, and GuruFocus emphasizes a significant rise in Eli Lilly (LLY) stock, with TradingKey reporting a move up of 6.15% on June 26. Other reports from Investor's Business Daily and Moomoo attribute the company's momentum to profit growth, obesity franchise developments, and Medicare GLP-1 access.
Future developments involve the formal EU approval process following the EMA/CHMP recommendations and the continued evaluation of pirtobrutinib's results in CLL clinical trials.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 5h ago.
Quick answers
What specific recommendation did the CHMP make regarding Jaypirca?
The CHMP recommended the approval of Jaypirca (pirtobrutinib) in the EU for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy.
How did Eli Lilly's stock react to the news?
Eli Lilly shares rose, with TradingKey reporting a 6.15% increase on June 26.
What other factors contributed to Eli Lilly's stock performance?
According to coverage, investors are focusing on obesity franchise momentum, Medicare GLP-1 access, and massive profit growth.
Coverage (18)
- Eli Lilly Stock Jumps 7% as Medicare Opens GLP-1 Access: What a $2,100 Target Means for Investors TIKR.com · 1d ago
- U.S. Stocks Move | Eli Lilly and Co (LLY.US) Rises Over 4% as Jaypirca Marketing Authorization Application Submitted to European Commission 富途牛牛 · 1d ago
- Eli Lilly Leads 5 Stocks Near Buy Points As The Market Rally Rotates Investor's Business Daily · 1d ago
- Eli Lilly Shares Jump as Investors Focus on Medicare GLP-1 Access and Obesity Franchise Momentum Moomoo · 1d ago
- CHMP Recommends Pirtobrutinib for EU Approval in CLL Across All Lines of Therapy OncLive · 1d ago
- Why Is Eli Lilly (LLY) Stock Soaring Today Yahoo Finance · 1d ago
- Lilly Hits Record High On Massive Profit Growth, Leads 28 Just Added To Best Stock Lists Investor's Business Daily · 1d ago
- Pirtobrutinib Plus Venetoclax Shows Promising Results in CLL Oncology News Central · 1d ago
- June 2026 batch of EMA/CHMP recommendations The Pharma Letter · 1d ago
- Why Is Eli Lilly (LLY) Stock Soaring Today The Globe and Mail · 1d ago
- Eli Lilly shares rise after EU panel backs expanded use of Jaypirca Yahoo Finance · 1d ago
- Matthew Davids' Comments on the New Phase 3 Results From the BRUIN CLL-322 Trial - Dana-Farber Oncodaily · 1d ago
- Eli Lilly (LLY) Gains EMA Support for Cancer and Diabetes Treatm GuruFocus · 1d ago
- Eli Lilly and Co Stock (LLY) Moved Up by 6.15% on Jun 26: Drivers Behind the Movement TradingKey · 1d ago
- Dr Ahn: Exploring Treatment-Free Remissions With Pirtobrutinib in CLL Targeted Oncology · 1d ago
- Why is Eli Lilly stock surging today? Investing.com · 1d ago
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy Yahoo Finance · 1d ago
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026 European Medicines Agency (EMA) · 1d ago broke it first
People, places & organizations
Topics
Related trends
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked
European regulators are recommending the revocation of marketing authorization for Amgen's rare-disease drug Tavneos following new data.
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America
Eli Lilly's CEO outlines the transformative potential of GLP-1s as new oral weight-loss medications enter development.